This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: As authors of the first article on the incidence of ticlopidine hydrochloride–associated thrombotic thrombocytopenic purpura (TTP) after coronary artery stenting,¹ we would like to comment on the follow-up article on this subject by Dr Steinhubl and colleagues.² Our incidence data indicated a frequency that is 3-fold as frequent as reported in their article (1 in 1600 vs 1 in 4800).^{1, 3} Moreover, as both Steinhubl et al and we have stated, case-finding by surveying interventional cardiologists is likely to underestimate the true frequency of this adverse effect. None of the cardiologists involved in the cases that we reposed was aware that TTP had occurred in their patients. Although we agree that limiting therapy to 2 weeks after stenting does not prevent the development of TTP, the occurrence of this syndrome is rare. Of the 61 known cases of ticlopidine-associated TTP in patients who received coronary artery stenting, only . . . [Full Text of this Article]